Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 vs Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT06382142Phase 3Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jan 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in triple-negative breast cancer (TNBC), sponsored by Biokin Pharmaceutical. Started Jun 2024; status: active, not recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06382142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06382142.